Downstream Processing Featured Articles

1. Newfound Gene May Help Bacteria Survive In Extreme Environments 7/25/2012

   In the days following the 2010 Deepwater Horizon oil spill, methane-eating bacteria bloomed in the Gulf of Mexico, feasting on the methane that gushed, along with oil, from the damaged well. The sudden influx of microbes was a scientific curiosity: Prior to the oil spill, scientists had observed relatively few signs of methane-eating microbes in the area. By Jennifer Chu, MIT

2. COVID-19 Consortium: Competitive Collab On A Plasma-Derived Therapy 12/14/2020

   A host of global biopharma competitors are collaborating under the CoVIg-19 Plasma Alliance to secure enough convalescent plasma to produce an effective COVID-19 therapeutic at global scale. Takeda’s Dr. Thomas R. Kreil will present at the upcoming FDA/Xavier PharmaLink Conference.

3. AdvantaPure®'s BioPharm Tubing And Single-Use Systems To Be Featured At Upcoming Fall Shows 9/9/2010
   High purity tubing manufacturer AdvantaPure will exhibit at three trade shows for the pharmaceutical and bioprocess industries this fall. Each exhibition will provide the company with opportunities to meet with customers and prospects, answer questions, and promote the continuing adoption of single use products.
4. Population Genetics Validates GenomePooling For Cancer 7/31/2012

   Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method’s suitability for use in IntReALL 2010, the world’s largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.

5. PBS Biotech Launches Single-Use Bioreactor For Development Of New Vaccines And Biosimilars 5/25/2011
   PBS Biotech, Inc., a developer of state of the art bioreactors to be used in the fast growing biotechnology market, announced recently the launch of its innovative PBS 3 single-use bioreactor system.
6. Avid Bioservices Announces Completion Of Facility Upgrades In Response To Increased Demand For Its Contract Manufacturing Services 12/13/2012

   Avid Bioservices, Inc, a contract manufacturing organization (CMO) focused on the process development and manufacturing of monoclonal antibodies, proteins and enzymes, today announced that its demand for services has reached an all-time high, while projected revenue for its current fiscal year ending April 2013 is expected to surpass $18 million, a 20% increase from the previous fiscal year.

7. Immunovative, Inc. Announces Expanded Collaboration With The University Of Arizona To Investigate AlloStim™ And AlloVax™ In Leukemias And Cancers That Affect Children 11/13/2012

   Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) has today announced that Immunovative Therapies, Ltd. ("ITL") and The University of Arizona Cancer Center (UACC) and The University of Arizona Medical Center (UAMC) (University Campus and Diamond Children's) have agreed to expand their current collaboration to include investigator-initiated clinical trials using AlloStim™ and AlloVax™, with an initial focus on adult and pediatric leukemias and childhood cancers that are refractory to standard treatments.

8. Researchers 'Switch Off' Neurodegeneration In Mice 5/11/2012

   Researchers at the Medical Research Council (MRC) Toxicology Unit at the University of Leicester have identified a major pathway leading to brain cell death in mice with neurodegenerative disease. The team was able to block the pathway, preventing brain cell death and increasing survival in the mice.

9. Dr. Brad Vince Of Vince & Associates Clinical Research Announces Award Of Nearly $10M Contract From The National Institute On Drug Abuse 9/19/2012

   Vince & Associates Clinical Research announced it has been awarded a contract with the National Institute on Drug Abuse, part of the National Institutes of Health (NIH), to carry out clinical pharmacology studies to determine the pharmacokinetics and pharmacodynamics of new medication in humans.

10. Protein Central To Cancer Stem Cell Formation Provides New Potential Target 2/13/2013

    Researchers have identified a pivotal protein in a cellular transformation that makes a cancer cell more resistant to treatment and more capable of growing and spreading, making it an inviting new target for drug development.